Oct. 8, 2013 – Although the Food and Drug Administration (FDA) has moved aggressively to approve new drugs recently, the FDA’s marketing policy priorities and its interpretation of the First Amendment do not always mesh with industry’s priorities, according to speakers at the Coalition for Healthcare Communication members meeting held recently in Washington, D.C. “Attendees […]
Read more